Driven by prescription drug prices and oft-repeated claims that nearly every drug developed in the U.S. owes its origins to taxpayer-funded research, watchdog groups and some lawmakers have led demands over the years for price to be considered a “reasonableness” factor in determining whether the government can march in on patents under the Bayh-Dole Act. Read More
CSL Ltd. is out-licensing its interleukin-6 (IL-6) monoclonal antibody, clazakizumab, to Eli Lilly and Co. in a deal that brings CSL $100 million in up-front fees. A CSL spokesperson told BioWorld the deal includes undisclosed milestone payments and sales-based royalties. CSL will retain rights to develop and commercialize clazakizumab for prevention of cardiovascular events in patients with end-stage kidney disease, while Lilly will explore the MAb in all other indications. Read More
Medtronic plc this week reported that the first commercial surgical cases using its Hugo robotic-assisted surgery system have been completed in the U.S. Hugo is expected to be a key growth driver for the company, especially with opportunities in the underpenetrated U.S. soft tissue surgical robotics market. The company also posted third-quarter fiscal year 2026 organic revenues of $9.02 billion, up 6% year‑on‑year. Read More
Infectious disease-focused biopharma companies continued their rebound into year-end, with the BioWorld Infectious Disease Index finishing 2025 up 68.55% after standing at a collective 28.98% at the end of October. The rally underscores a sharp reversal from earlier in the year, when the index had declined 17.83% by the end of April before recovering to a 4.34% gain by July. Read More
At a time of global transition for life sciences, with China stepping up the pace of innovation and the U.S. adopting protectionist policies, the health innovation region in Catalonia, Spain, is emerging as one of the most dynamic hubs in Europe. Last year, the region, centered on Barcelona, saw growth of 8.3% over 2024, and there are now 1,650 companies, including 423 biotechs, 259 digital health specialists and 238 med techs. Read More
SLAMF6 is an immune cell receptor whose function was not clear. Does it activate or inhibit cells? The results so far have been contradictory. Now, scientists at the Institut de Recherches Cliniques de Montréal have unveiled evidence that SLAMF6, a protein of the SLAM family that binds to copies of itself, is regulated by interactions between molecules of the same receptor within the same cell. Read More
New hires and promotions in the biopharma and med-tech industries, including: Aquestive, Aspargo, Cranius, Eyepoint, Immorta, Integra, Lixte, Liora, Tarsus, Tenvie. Read More
Biopharma and med-tech companies raising money in public or private financings, including: Appili, EIR, HCW, Korsana, Prosomnus, Senzime, Synchrony, Tele Genomics. Read More
Clinical updates for biopharma and med tech, including data readouts and publications: Aprea, Eli Lilly, Moleculin, Neurosense, Novartis, PLL, Zealand. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Axol, Izotropic, Newcells, Rasayana, Stoked, Theriva. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Affinia, Biomerica, Hardy, Helsinn, Immunitybio, Instanosis, Johnson & Johnson, Moderna, NG, Sandoz, Shield, Spruce, Telix. Read More
